TY - JOUR
T1 - Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis
T2 - A global cohort study
AU - Semenchuk, Julie
AU - Naito, Yumi
AU - Charman, Susan C.
AU - Carr, Siobhán B.
AU - Cheng, Stephanie Y.
AU - Marshall, Bruce C.
AU - Faro, Albert
AU - Elbert, Alexander
AU - Gutierrez, Hector H.
AU - Goss, Christopher H.
AU - Karadag, Bulent
AU - Burgel, Pierre Régis
AU - Colombo, Carla
AU - Salvatore, Marco
AU - Padoan, Rita
AU - Daneau, Géraldine
AU - Harutyunyan, Satenik
AU - Kashirskaya, Nataliya
AU - Kirwan, Laura
AU - Middleton, Peter G.
AU - Ruseckaite, Rasa
AU - de Monestrol, Isabelle
AU - Naehrlich, Lutz
AU - Mondejar-Lopez, Pedro
AU - Jung, Andreas
AU - van Rens, Jacqui
AU - Bakkeheim, Egil
AU - Orenti, Annalisa
AU - Zomer-van Ommen, Domenique
AU - da Silva-Filho, Luiz Vicente RF
AU - Fernandes, Flavia Fonseca
AU - Zampoli, Marco
AU - Stephenson, Anne L.
AU - Kasmi, Irena
AU - Drali, Ouardia
AU - Burghart, Sabine
AU - Lakatos-Krepcik, Andrea
AU - Eder, Johannes
AU - Jaksch, Peter
AU - Kainz, Katharina
AU - Kallinger, Margit
AU - Leitner, Alexander
AU - Mozdzen, Marta
AU - Pfleger, Andreas
AU - Renner, Sabine
AU - Stadlinger, Martin
AU - Thir, Christina
AU - Nuriyev, Emil
AU - Boboli, Hedwige
AU - De Wachter, Elke
AU - Global CF Registry Collaboration
AU - Bannier, Michiel
AU - Wesseling, Geertjan
N1 - Funding Information:
We would like to acknowledge and thank all the pwCF and their families who consented to be part of their respective CF patient registries as well as the CF clinic staff who spend many hours inputting the data. In addition, we would like to thank all the individuals in countries without established registries for their significant effort to capture the data in their respective clinics or countries. We would like to thank the staff at the European CF Society Registry, in particular Alice Fox and Marko Krasnyk. Presentation: Data were presented as a poster abstract and oral presentation at the North American CF Conference in November 2023 in Phoenix, Arizona. Study concept and design: ALS, SYC, Analysis and interpretation of data: All, Drafting of the manuscript: JS, ALS, SCC, YN, SYC, Critical revision of the manuscript for important intellectual content: All, Statistical analysis: SCC, YN, Study supervision: ALS, Canadian Institutes for Health Research (CIHR)
Publisher Copyright:
© 2024
PY - 2024/9/1
Y1 - 2024/9/1
N2 - Background: Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF). Methods: This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021. Forced expiratory volume in one second percent predicted (ppFEV1) and body mass index (BMI) twelve months prior to and following a diagnosis of COVID-19 were recorded. Change in mean ppFEV1 and BMI were compared using a t-test. A linear mixed-effects model was used to estimate change over time and to compare the rate of change before and after infection. Results: A total of 6,500 cases of COVID-19 in pwCF from 33 countries were included for analysis. The mean difference in ppFEV1 pre- and post-infection was 1.4 %, (95 % CI 1.1, 1.7). In those not on modulators, the difference in rate of change pre- and post-infection was 1.34 %, (95 % CI -0.88, 3.56) per year (p = 0.24) and -0.74 % (-1.89, 0.41) per year (p = 0.21) for those on elexacaftor/tezacaftor/ivacaftor. No clinically significant change was noted in BMI or BMI percentile before and after COVID-19 infection. Conclusions: No clinically meaningful impact on lung function and BMI trajectory in the year following infection with COVID-19 was identified. This work highlights the ability of the global CF community to unify and address critical issues facing pwCF.
AB - Background: Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF). Methods: This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021. Forced expiratory volume in one second percent predicted (ppFEV1) and body mass index (BMI) twelve months prior to and following a diagnosis of COVID-19 were recorded. Change in mean ppFEV1 and BMI were compared using a t-test. A linear mixed-effects model was used to estimate change over time and to compare the rate of change before and after infection. Results: A total of 6,500 cases of COVID-19 in pwCF from 33 countries were included for analysis. The mean difference in ppFEV1 pre- and post-infection was 1.4 %, (95 % CI 1.1, 1.7). In those not on modulators, the difference in rate of change pre- and post-infection was 1.34 %, (95 % CI -0.88, 3.56) per year (p = 0.24) and -0.74 % (-1.89, 0.41) per year (p = 0.21) for those on elexacaftor/tezacaftor/ivacaftor. No clinically significant change was noted in BMI or BMI percentile before and after COVID-19 infection. Conclusions: No clinically meaningful impact on lung function and BMI trajectory in the year following infection with COVID-19 was identified. This work highlights the ability of the global CF community to unify and address critical issues facing pwCF.
KW - Coronavirus
KW - COVID-19
KW - Cystic fibrosis
U2 - 10.1016/j.jcf.2024.07.019
DO - 10.1016/j.jcf.2024.07.019
M3 - Article
SN - 1873-5010
VL - 23
SP - 815
EP - 822
JO - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
JF - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
IS - 5
ER -